Results 11 to 20 of about 7,885 (162)

Application of Hydrate-Melt Electrolytes to High-Rate and High-Capacity Organic Lithium-Ion Batteries. [PDF]

ChemSusChem
Stable redox reactions of lithium croconate organic cathode materials are achieved in water‐based hydrate‐melt electrolytes. The unique solution structure of hydrate‐melt electrolytes, an extremely low‐water‐activity environment, suppresses dissolution and decomposition, enabling high‐energy‐density aqueous rechargeable batteries.
Gambe Y, Ohno S, Honma I.
europepmc   +2 more sources

Nurbaiti, Beti. Buku Ajar : Pengolahan Data Dengan Lisrel ISBN : 978-623-315-078-1 Penerbit CV. Pena Persada [PDF]

, 2021
Assalamualaikum Wr Wb Alhamdulilah, segala puji syukur saya haturkan sebagai penulis, karena dengan limpahan Allah SWT, karena berkat Rahmat dan RidhoNya, buku ini dapat selesai disusun dengan melewati berbagai rintangan dan proses penyusunannya yang ...
Nurbaiti, beti
core   +1 more source

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53

Neoplasia: An International Journal for Oncology Research, 2021
Amplification of MYCN is a poor prognostic feature in neuroblastoma (NBL) indicating aggressive disease. We and others have shown BET bromodomain inhibitors (BETi) target MYCN indirectly by downregulating its transcription.
Joanna S. Yi, Oscar Sias-Garcia, Nicole Nasholm, Xiaoyu Hu, Amanda Balboni Iniguez, Matthew D. Hall, Mindy Davis, Rajarshi Guha, Myrthala Moreno-Smith, Eveline Barbieri, Kevin Duong, Jessica Koach, Jun Qi, James E. Bradner, Kimberly Stegmaier, William A. Weiss, W. Clay Gustafson   +16 more
doaj   +1 more source

Concurrent targeting of MAP3K3 and BRD4 by miR-3140-3p overcomes acquired resistance to BET inhibitors in neuroblastoma cells

Molecular Therapy: Nucleic Acids, 2021
Neuroblastoma (NB) harboring MYCN amplification is a refractory disease with a poor prognosis. As BRD4, an epigenetic reader belonging to the bromodomain and extra terminal domain (BET) family, drives transcription of MYCN in NB cells, BET inhibitors ...
Chang Liu, Yasuyuki Gen, Kousuke Tanimoto, Tomoki Muramatsu, Jun Inoue, Johji Inazawa   +5 more
doaj   +1 more source

BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells

Journal of Experimental & Clinical Cancer Research, 2023
Background Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that differs from other types of breast cancers in the faster spread and worse outcome. TNBC presented limited treatment options.
Teresa Rossi, Raffaella Zamponi, Mattea Chirico, Maria Elena Pisanu, Egidio Iorio, Federica Torricelli, Mila Gugnoni, Alessia Ciarrocchi, Mariaelena Pistoni   +8 more
doaj   +1 more source

BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations

Genes and Diseases, 2023
The bromodomain and extra-terminal (BET) proteins act as “readers” for lysine acetylation and facilitate the recruitment of transcriptional elongation complexes.
Tao Ma, Yan Chen, Zhi-Gang Yi, Yan-Hong Li, Jun Bai, Li-Juan Li, Lian-Sheng Zhang   +6 more
doaj   +1 more source

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression

Cell Death and Disease, 2022
Bromodomain and extra-terminal tail (BET) proteins have been identified as potential epigenetic targets in cancer, including glioblastoma. These epigenetic modifiers link the histone code to gene transcription that can be disrupted with small molecule ...
Alessandro Tancredi, Olga Gusyatiner, Pierre Bady, Michelle C. Buri, Rémy Lomazzi, Davide Chiesi, Mahmoud Messerer, Monika E. Hegi   +7 more
doaj   +1 more source

The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells

Frontiers in Oncology, 2022
We reported previously that the BET inhibitor (BETi) JQ1 decreases levels of the DNA repair protein RAD51 and that this decrease is concomitant with increased levels of DNA damage.
Patrick L. Garcia, Aubrey L. Miller, Ling Zeng, Ling Zeng, Robert C. A. M. van Waardenburg, Eddy S. Yang, Eddy S. Yang, Eddy S. Yang, Karina J. Yoon   +8 more
doaj   +1 more source

Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancerResearch in context

EBioMedicine, 2019
Background: Bromodomain and extra-terminal inhibitors (BETi) have shown efficacy for the treatment of aggressive triple negative breast cancer (TNBC).
Sushmita Mustafi, Vladimir Camarena, Rehana Qureshi, Hyunho Yoon, Claude-Henry Volmar, Tyler C. Huff, David W. Sant, Lihong Zheng, Shaun P. Brothers, Claes Wahlestedt, Joyce Slingerland, Gaofeng Wang   +11 more
doaj   +1 more source

Study the properties of a chickpea-based jelly product [PDF]

E3S Web of Conferences, 2021
The consumption of food products with low consumer properties is the reason for a decrease in a life quality as well as for a number of diseases development among the population.
Molchanova Elena, Shipareva Marya, Evmeshkina Tatyana, Isabayev Ismoil   +3 more
doaj   +1 more source